Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2002 Apr 6;359(9313):1221–1231. doi: 10.1016/S0140-6736(02)08220-X
   PubMed Web of Science ®Google Scholar
• McKay KA, Kwan V, Duggan T, et al. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. BioMed Res Int. 2015;2015:817238.
   PubMed Web of Science ®Google Scholar
• The Multiple Sclerosis International Federation. Atlas of MS. 3rd Edition; Sep 2020. cited 2023 May. Available from: https://www.msif.org/wp-content/uploads/2020/12/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf
   Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30(2):89–100. doi: 10.2165/11533330-000000000-00000
   PubMed Web of Science ®Google Scholar
• Sauri-Suarez S, Quinones-Aguilar S, Contreras-Marin A, et al. Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis. PLoS ONE. 2020;15(4):e0230959. doi: 10.1371/journal.pone.0230959
   PubMed Web of Science ®Google Scholar
• Mardan J, Hussain MA, Allan M, et al. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27(9):1273–1295. doi: 10.18553/jmcp.2021.27.9.1273
   PubMed Web of Science ®Google Scholar
• Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011 May;38(3):429–433.
   PubMed Web of Science ®Google Scholar
• Hansen K, Schussel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS ONE. 2015;10(7):e0133279. doi: 10.1371/journal.pone.0133279
   PubMed Web of Science ®Google Scholar
• Moccia M, Palladino R, Carotenuto A, et al. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Mult Scler Relat Disord. 2016;10:90–96.
   PubMed Web of Science ®Google Scholar
• Sabido-Espin M, Munschauer R. Reasons for discontinuation of subcutaneous interferon beta-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC neurol. 2017 Mar 23;17(1):57. doi: 10.1186/s12883-017-0831-4
   PubMed Web of Science ®Google Scholar
• Merck Europe B.V. Rebif (Summary of Product Characteristics). Amsterdam, The Netherlands; 2021. https://www.ema.europa.eu/documents/product-information/rebif-epar-product-information_en.pdf
   Google Scholar
• Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015 Aug;12(8):1239–1250.
   PubMed Web of Science ®Google Scholar
• Devonshire VA, Feinstein A, Moriarty P. Adherence to interferon beta-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study. BMC Res Notes. 2016;9:148.
   PubMedGoogle Scholar
• Edo Solsona MD, Monte Boquet E, Casanova Estruch B, et al. Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by RebiSmart® in patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:415–421.
   PubMed Web of Science ®Google Scholar
• Lugaresi A, De Robertis F, Clerico M, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon beta-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016;13(7):931–935. doi: 10.1517/17425247.2016.1148029
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Ziemssen T, Penner IK, et al. Adherence to subcutaneous interferon beta-1a in multiple sclerosis patients receiving periodic feedback on drug use by discussion of readouts of their RebiSmart® injector: results of the prospective cohort study REBIFLECT. Adv Ther. 2022;39(6):2749–2760. doi: 10.1007/s12325-022-02100-w
   PubMed Web of Science ®Google Scholar
• Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC neurol. 2010;10(1):28. doi: 10.1186/1471-2377-10-28
   PubMedGoogle Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC neurol. 2012;12:7.
   PubMed Web of Science ®Google Scholar
• Moccia M, Palladino R, Russo C, et al. How many injections did you miss last month? A simple question to predict interferon beta-1a adherence in multiple sclerosis. Expert Opin Drug Deliv. 2015;12(12):1829–1835. doi: 10.1517/17425247.2015.1078789
   PubMed Web of Science ®Google Scholar
• Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart® injection device. Patient Prefer Adherence. 2014;8:843–851.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368–1374. doi: 10.1136/jnnp.2008.145805
   PubMed Web of Science ®Google Scholar
• Allignol A, Boutmy E, Sabido Espin M, et al. Effectiveness, healthcare resource utilization and adherence to subcutaneous interferon beta-1a according to age in patients with multiple sclerosis: a cohort study using a US claims database. Front Neurol. 2021;12:676585.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Spelman T, Trojano M, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS ONE. 2013;8(5):e63480. doi: 10.1371/journal.pone.0063480
   PubMedGoogle Scholar
• Colten S, Verdun Di Cantogno E, Jack D. Uncovering nurses’ and patients’ preferences and perceptions of Rebismart® 3.0 autoinjector versus other assistive devices in multiple sclerosis. Mult Scler Relat Disord. 2023;71(104259):10–11.
   Google Scholar